December 9, 2021: Apogenix AG

Apogenix Receives €20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

Main investor dievini supports project with additional €5.1 million
Apogenix is one of six therapeutics developers in Germany selected to receive funding totaling €150 million

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received a funding commitment from the German Federal Ministries of Health (BMG) and Education and Research (BMBF) in the amount of €20.7 million as part of the funding initiative “Clinical development of COVID-19 drugs and their manufacturing capabilities.” At the beginning of September, the two ministries held a press conference to announce the companies that had been selected for funding. Apogenix has just received the official funding notice. The funds will be used to finance a phase III clinical trial (ASUCOV) with CD95 ligand inhibitor asunercept in moderately to severely ill, hospitalized COVID-19 patients. In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced. The German government will fund 80 percent of these costs, and the remaining 20 percent will be covered by Apogenix’s main investor dievini Hopp BioTech Holding GmbH & Co. KG.

Please read the whole article here

News 2021

December 22, 2020: Apogenix AG

COVID-19: targeted treatment trial launched in Vienna

A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG, a biotech company based in Heidelberg, and their scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).

Please read the whole article here

News 2020

October 13, 2020: Apogenix AG

Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that the first patient has been enrolled in the ASUNCTIS trial. The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease. In four treatment arms, three different doses of asunercept plus standard of care versus standard of care alone are being evaluated in a total of 400 patients. Apogenix has received regulatory approval for the ASUNCTIS trial now in both Spain and Russia and will enroll patients in multiple study centers in Madrid and Saint Petersburg, among others.

Please read the whole article here

News 2020

July 28, 2020: Apogenix AG

Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease. The plan is to include additional study centers in other European countries, in particular Spain. Published data indicate that the CD95 ligand (CD95L) – the target of asunercept – plays a role in the induction of life-threatening lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients. By blocking CD95L, asunercept could reduce these complications reported in COVID-19 patients.

Please read the whole article here

News 2020

June 17, 2020: Apogenix AG

Apogenix to Present at AACR Virtual Annual Meeting II

Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the AACR Virtual Annual Meeting II, which takes place online from June 22-24, 2020. Participation will be free to everyone, but registration is required to view the meeting.

Please read the whole article here

News 2020

December 5, 2019: Apogenix AG

Apogenix to Present New Data on Asunercept at ESMO Immuno-Oncology Congress

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data on its lead immuno-oncology candidate asunercept will be presented in a poster at the ESMO Immuno-Oncology Congress 2019, held from December 11-14, 2019, at the Palexpo in Geneva, Switzerland. The data are the result of a research collaboration with Benoit Van den Eynde and his team from the Ludwig Institute for Cancer Research in Brussels, Belgium.

Please read the whole article here

News 2019

November 7, 2019: Apogenix AG

Strong Quality of Life Data for Apogenix’ Asunercept Published in Journal of Neuro-Oncology

Asunercept Plus Radiotherapy Significantly Prolongs Time to Deterioration of Quality of Life Compared to Radiotherapy Alone in Patients with Recurrent Glioblastoma

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that a new publication in Journal of Neuro-Oncology1 shows that in patients with recurrent glioblastoma, treatment with asunercept in combination with radiotherapy is associated with a statistically significant prolongation in time to deterioration of quality of life beyond progression of the disease compared to treatment with radiotherapy alone.

Please read the whole article here

News 2019

October 10, 2019: Apogenix AG

Apogenix to Present at Several Upcoming International Conferences

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will attend several upcoming international conferences. In two presentations, Apogenix will give updates on TNF superfamily receptor agonists HERA-CD40L and HERA-GITRL. The company will further present a poster on the therapeutic benefit of orphan drugs in oncology.

Please read the whole article here

News 2019

September 24, 2019: Apogenix AG

ESMO and Apogenix Collaborate on “Recurrent Glioblastoma Management: Challenges and Opportunities” Colloquium

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain. The chairs and speakers – all international experts in the glioblastoma field – will discuss the current standard of care for recurrent glioblastoma, novel treatment approaches, the role and biological mechanisms of the CD95/CD95 ligand (Fas/Fas ligand) pathway, as well as the rationale and clinical results of CD95 ligand/Fas ligand inhibition.

Please read the whole article here

News 2019

September 19, 2019: Apogenix AG

Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that a new publication in Human Vaccines & Immunotherapeutics highlights the advantages of hexavalent CD40 agonists, such as HERA-CD40L, in the targeting of CD40 in immuno-oncology. Apogenix was invited to write this review paper of the various concepts for agonistic targeting of CD40 in immuno-oncology.

Please read the whole article here

News 2019